Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Precision Medicine: From Science To ValueHealth Affairs, 2018-05, Vol.37 (5), p.694-701 [Peer Reviewed Journal]Copyright The People to People Health Foundation, Inc., Project HOPE May 2018 ;ISSN: 0278-2715 ;EISSN: 1544-5208 ;EISSN: 2694-233X ;DOI: 10.1377/hlthaff.2017.1624 ;PMID: 29733705Full text available |
|
2 |
Material Type: Article
|
Stakeholders welcome proposal on the European Health Data SpaceThe lancet oncology, 2022-12, Vol.23 (12), p.1492-1492 [Peer Reviewed Journal]2022 Elsevier Ltd ;2022. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(22)00691-X ;PMID: 36335972Full text available |
|
3 |
Material Type: Article
|
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumorsThe Journal of clinical investigation, 2019-05, Vol.129 (5), p.2056-2070 [Peer Reviewed Journal]COPYRIGHT 2019 American Society for Clinical Investigation ;COPYRIGHT 2019 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation May 2019 ;2019 American Society for Clinical Investigation 2019 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/JCI99538 ;PMID: 30835255Full text available |
|
4 |
Material Type: Article
|
The importance of patient-reported outcomes in clinical trials and strategies for future optimizationPatient related outcome measures, 2018-01, Vol.9, p.353-367 [Peer Reviewed Journal]COPYRIGHT 2018 Dove Medical Press Limited ;COPYRIGHT 2018 Dove Medical Press Limited ;2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Mercieca-Bebber et al. This work is published and licensed by Dove Medical Press Limited 2018 ;ISSN: 1179-271X ;EISSN: 1179-271X ;DOI: 10.2147/prom.s156279 ;PMID: 30464666Full text available |
|
5 |
Material Type: Article
|
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet (British edition), 2012-03, Vol.379 (9822), p.1214-1224 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 31-Apr 6, 2012 ;2012 Elsevier Ltd. All rights reserved. 2012 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60110-X ;PMID: 22421340 ;CODEN: LANCAOFull text available |
|
6 |
Material Type: Article
|
Global post-mortem tissue donation programmes to accelerate cancer researchNature reviews. Cancer, 2024-05, Vol.24 (5), p.289-290 [Peer Reviewed Journal]Springer Nature Limited 2024. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-024-00683-w ;PMID: 38589555Digital Resources/Online E-Resources |
|
7 |
Material Type: Article
|
Raise standards for preclinical cancer researchNature (London), 2012-03, Vol.483 (7391), p.531-533 [Peer Reviewed Journal]Copyright Nature Publishing Group Mar 29, 2012 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/483531a ;CODEN: NATUASFull text available |
|
8 |
Material Type: Article
|
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesThe Lancet (British edition), 2013-05, Vol.381 (9880), p.1817-1826 [Peer Reviewed Journal]Elsevier Ltd ;2013 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 25, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)60313-X ;PMID: 23615461 ;CODEN: LANCAOFull text available |
|
9 |
Material Type: Article
|
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialThe lancet oncology, 2021-08, Vol.22 (8), p.1162-1174 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00302-8Full text available |
|
10 |
Material Type: Article
|
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet (British edition), 2011-06, Vol.377 (9784), p.2181-2192 [Peer Reviewed Journal]Elsevier Ltd ;2011 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 25-Jul 1, 2011 ;2011 Elsevier Ltd. All rights reserved. 2011 Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(11)60739-3 ;PMID: 21663949 ;CODEN: LANCAOFull text available |
|
11 |
Material Type: Article
|
A decade of immune-checkpoint inhibitors in cancer therapyNature communications, 2020-07, Vol.11 (1), p.3801-3801, Article 3801 [Peer Reviewed Journal]The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-17670-y ;PMID: 32732879Full text available |
|
12 |
Material Type: Article
|
What advanced cancer patients with limited treatment options know about clinical research: a qualitative studySupportive care in cancer, 2017-10, Vol.25 (10), p.3235-3242 [Peer Reviewed Journal]Springer-Verlag Berlin Heidelberg 2017 ;COPYRIGHT 2017 Springer ;Supportive Care in Cancer is a copyright of Springer, 2017. ;ISSN: 0941-4355 ;EISSN: 1433-7339 ;DOI: 10.1007/s00520-017-3734-4 ;PMID: 28488050Full text available |
|
13 |
Material Type: Article
|
Global cancer research in the post-pandemic worldThe lancet oncology, 2021-12, Vol.22 (12), p.1652-1654 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00602-1 ;PMID: 34856137Full text available |
|
14 |
Material Type: Article
|
Are innovation and new technologies in precision medicine paving a new era in patients centric care?Journal of translational medicine, 2019-04, Vol.17 (1), p.114-114, Article 114 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1479-5876 ;EISSN: 1479-5876 ;DOI: 10.1186/s12967-019-1864-9 ;PMID: 30953518Full text available |
|
15 |
Material Type: Article
|
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitorsNature reviews. Drug discovery, 2018-11, Vol.17 (12), p.854-855 [Peer Reviewed Journal]Copyright Nature Publishing Group Dec 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.210Full text available |
|
16 |
Material Type: Article
|
WHO, WHAT AND WHERE IS THE CLINICAL TRANSLATIONAL RESEARCH CENTEROncology nursing forum, 2022-03, Vol.49 (2), p.E134-E135 [Peer Reviewed Journal]Copyright Oncology Nursing Society Mar 2022 ;ISSN: 0190-535X ;EISSN: 1538-0688Full text available |
|
17 |
Material Type: Article
|
Gastric cancerThe Lancet (British edition), 2020-08, Vol.396 (10251), p.635-648 [Peer Reviewed Journal]2020 Elsevier Ltd ;2020. Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31288-5Full text available |
|
18 |
Material Type: Article
|
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020-03, Vol.21 (3), p.335-337 [Peer Reviewed Journal]2020 Elsevier Ltd ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30096-6 ;PMID: 32066541Digital Resources/Online E-Resources |
|
19 |
Material Type: Article
|
Translational research in neuroendocrine tumors: pitfalls and opportunitiesOncogene, 2017-04, Vol.36 (14), p.1899-1907 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Apr 6, 2017 ;Macmillan Publishers Limited, part of Springer Nature. 2017. ;ISSN: 0950-9232 ;EISSN: 1476-5594 ;DOI: 10.1038/onc.2016.316 ;PMID: 27641330 ;CODEN: ONCNESFull text available |
|
20 |
Material Type: Article
|
CANCER CLINICAL TRIAL TUMOR BOARD – A METHOD TO INCREASE TRIAL ENROLLMENTSOncology nursing forum, 2024-03, Vol.51 (2), p.17C-18C [Peer Reviewed Journal]Copyright Oncology Nursing Society Mar 2024 ;ISSN: 0190-535X ;EISSN: 1538-0688Digital Resources/Online E-Resources |